BMRNHIGH SIGNALRISK10-K

BioMarin is pursuing a major acquisition of Amicus Therapeutics, introducing substantial new risks around deal completion, integration challenges, and material transaction expenses.

The addition of multiple Amicus acquisition risk factors represents a significant strategic shift that could fundamentally alter BioMarin's business profile and capital allocation. The specific callouts around timeline uncertainty, potential failure to realize benefits, and material expenses suggest this is a large, complex transaction that management views as carrying substantial execution risk.

Comparing 2026-02-26 vs 2025-02-24View on EDGAR →
FINANCIAL ANALYSIS

BioMarin shows strong top-line growth with revenue increasing 17.6% and operating cash flow surging 44.5%, while cash position strengthened significantly to $1.3B. However, profitability declined with net income falling 18.3% and operating income down 15.4%, primarily due to a 23.4% increase in R&D spending to $921.9M. The combination of strong cash generation, increased receivables, and higher current liabilities suggests aggressive growth investments, likely positioning for the pending Amicus acquisition.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+44.5%
$572.8M→$828.0M

Operating cash flow surged 44.5% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
+39.1%
$942.8M→$1.3B

Cash position surged 39.1% — strong cash generation or capital raise providing significant financial cushion.

Accounts Receivable
Balance Sheet
+37.5%
$660.5M→$908.2M

Receivables surged 37.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Liabilities
Balance Sheet
+25%
$607.0M→$759.0M

Current liabilities rose 25% — increased short-term obligations, watch current ratio.

R&D Expense
P&L
+23.4%
$747.2M→$921.9M

R&D investment increased 23.4% — signals commitment to future product development, though near-term margin impact.

Current Assets
Balance Sheet
+22.3%
$3.2B→$4.0B

Current assets grew 22.3% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
+20.6%
$85.4M→$103.0M

Capex increased 20.6% — ongoing investment in capacity or infrastructure for future growth.

Net Income
P&L
-18.3%
$426.9M→$348.9M

Net income declined 18.3% — review whether driven by operations, interest costs, or non-recurring items.

Revenue
P&L
+17.6%
$1.1B→$1.3B

Revenue growing 17.6% — solid top-line momentum, watch margins for quality of growth.

Operating Income
P&L
-15.4%
$484.2M→$409.5M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-24
ADDED
As of February 19, 2026, the registrant had 192,323,359 shares of common stock, par value $0.001, outstanding.
We have in the past and may in the future pursue acquisitions of other companies or businesses, which could divert our management's attention, fail to achieve the anticipated benefits and/or expose us to other risks or difficulties.
Amicus Acquisition Risks The pending Amicus Acquisition may not be completed on the currently contemplated timeline or terms, or at all.
We may not realize the anticipated benefits from the pending Amicus Acquisition.
3 The pendency of the Amicus Acquisition could adversely affect our and/or Amicus' businesses and operations.
We expect to incur material expenses related to the Amicus Acquisition.
We may not realize the anticipated cost savings from the Amicus Acquisition.
We have incurred in the past and may in the future incur substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which may adversely affect our operations and financial results.
(BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions.
Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline.
REMOVED
As of February 18, 2025, the registrant had 190,777,052 shares of common stock, par value $0.001, outstanding.
We have in the past entered and may in the future enter into licensing arrangements, and we may not realize the benefits of such licensing arrangements.
(BioMarin, we, us or our) is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient.
The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline.
Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult to treat genetic conditions.
Recent Developments In 2024, we achieved $2.9 billion in total revenues, including a significant contribution from our ongoing expansion of VOXZOGO, and we continued making important advancements in our product development pipeline.
In the first half of 2024, we focused on value creation through working to accelerate growth, optimize efficiencies and drive operational excellence, including progress in executing on key strategic priorities first outlined in January 2024.
We also completed a strategic portfolio assessment of research and development programs to determine which we believe have the strongest combination of scientific merit, opportunity for commercial success and potential value creation for stockholders.
In September 2024, we held an Investor Day, during which we provided an overview of our new corporate strategy focused on innovation, growth, and value commitment.
Our new strategy includes, among other things, our plans to expand VOXZOGO for the treatment of conditions beyond achondroplasia, our initiatives to drive sustained growth of the Enzyme Therapies portfolio (ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ and VIMIZIM), and our decision to focus on the United States (U.S.), Germany and Italy with respect to ROCTAVIAN.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →